|
Diabetes, Vol 47, Issue 9 1459-1463, Copyright © 1998 by American Diabetes Association
Glucose utilization and production in patients with maturity-onset diabetes of the young caused by a mutation of the hepatocyte nuclear factor-1alpha gene
JF Surmely, E Guenat, J Philippe, P Dussoix, P Schneiter, E Temler, M Vaxillaire, P Froguel, E Jequier and L Tappy
Institute of Physiology, University of Lausanne, Switzerland.
Mutations of the hepatocyte nuclear factor (HNF)-1alpha gene cause impaired
insulin secretion and hyperglycemia in patients with maturity-onset
diabetes of the young (MODY)3. Whether these mutations also affect glucose
metabolism in tissues other than the beta-cell has not yet been documented.
We therefore assessed, in five MODY3 patients and a dozen healthy control
subjects, insulin secretion, oxidative and nonoxidative glucose disposal,
and glucose production during a two-step hyperglycemic clamp and a
euglycemic hyperinsulinemic (0.4 mU x kg(-1) x min(-1)) clamp. Compared
with healthy control subjects, MODY3 patients had higher fasting plasma
glucose (+100%) but similar rates of fasting glucose production and
oxidation. Both the early and late phases of insulin secretion were
virtually abolished during the hyperglycemic clamp, and glucose production
was suppressed by only 43% in MODY3 patients vs. 100% in healthy control
subjects. The rate of glucose infusion required to produce a 5 mmol/l
increase above basal glycemia was reduced by 30%, net nonoxidative glucose
disposal (which is equal to net glycogen deposition) was inhibited by 39%,
and net carbohydrate oxidation during hyperglycemia was 25% lower in MODY3
patients compared with control subjects. Insulin-stimulated glucose
utilization and oxidation measured during the hyperinsulinemic clamp (at
approximately 200 pmol/l insulin) were identical in MODY3 patients and in
healthy control subjects, indicating that peripheral insulin sensitivity
was not altered. Suppression of endogenous glucose production was, however,
mildly impaired. It is concluded that MODY3 patients have severely
depressed glucose-induced insulin secretion. The development of
hyperglycemia in these patients appears to be caused by a decreased
stimulation of glucose utilization, oxidation, and nonoxidative glucose
disposal as well as by a blunted suppression of endogenous glucose output.
These phenomena are essentially secondary to insulinopenia, whereas insulin
sensitivity remains intact.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Brackenridge, E. R. Pearson, F. Shojaee-Moradie, A. T. Hattersley, D. Russell-Jones, and A. M. Umpleby
Contrasting Insulin Sensitivity of Endogenous Glucose Production Rate in Subjects With Hepatocyte Nuclear Factor-1{beta} and -1{alpha} Mutations
Diabetes,
February 1, 2006;
55(2):
405 - 411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Habener, D. M. Kemp, and M. K. Thomas
Minireview: Transcriptional Regulation in Pancreatic Development
Endocrinology,
March 1, 2005;
146(3):
1025 - 1034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ferrer
A Genetic Switch in Pancreatic {beta}-Cells: Implications for Differentiation and Haploinsufficiency
Diabetes,
August 1, 2002;
51(8):
2355 - 2362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Hagenfeldt-Johansson, P. L. Herrera, H. Wang, A. Gjinovci, H. Ishihara, and C. B. Wollheim
{beta}-Cell-Targeted Expression of a Dominant-Negative Hepatocyte Nuclear Factor-1{alpha} Induces a Maturity-Onset Diabetes of the Young (MODY)3-Like Phenotype in Transgenic Mice
Endocrinology,
December 1, 2001;
142(12):
5311 - 5320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Westerlund and P. Bergsten
Glucose Metabolism and Pulsatile Insulin Release From Isolated Islets
Diabetes,
August 1, 2001;
50(8):
1785 - 1790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C. Chiu, L.-M. Chuang, J. M. Ryu, G. P. Tsai, and M. F. Saad
The I27L Amino Acid Polymorphism of Hepatic Nuclear Factor-1{alpha} Is Associated with Insulin Resistance
J. Clin. Endocrinol. Metab.,
June 1, 2000;
85(6):
2178 - 2183.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. A. Hegele, H. Cao, S. B. Harris, A. J. G. Hanley, B. Zinman, and P. W. Connelly
The Private Hepatocyte Nuclear Factor-1{alpha} G319S Variant Is Associated With Plasma Lipoprotein Variation in Canadian Oji-Cree
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2000;
20(1):
217 - 222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Hegele, H. Cao, S. B. Harris, A. J. G. Hanley, and B. Zinman
The Hepatic Nuclear Factor-1{alpha} G319S Variant Is Associated with Early-Onset Type 2 Diabetes in Canadian Oji-Cree
J. Clin. Endocrinol. Metab.,
March 1, 1999;
84(3):
1077 - 1082.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1998 by the American Diabetes Association.
|
|
| |
|